OxyContin Patents Invalid Due To Purdue’s Inequitable Conduct, Court Says
Executive Summary
A trial court ruling invalidating OxyContin (controlled-release oxycodone) patents hinges on the interpretation of the term "discovery" in Purdue's patent applications
You may also be interested in...
Purdue To Market Palladone With Fewer Reps After Halving Sales Force
Purdue will promote Palladone (hydromorphone extended-release) with significantly fewer reps after laying off half its sales force
Purdue To Market Palladone With Fewer Reps After Halving Sales Force
Purdue will promote Palladone (hydromorphone extended-release) with significantly fewer reps after laying off half its sales force
OxyContin ANDA Approval Delay Requested By Purdue In Petition To FDA
Purdue plans to submit a supplemental OxyContin application to include in labeling a toll-free number through which patients can get a copy of the opioid's risk management program